Phase 3b for MSI-H or MMR Colorectal Cancer Patients

A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT04008030?term=04008030&draw=2&rank=1